Once-daily dosing with JAKAFI XR™ (ruxolitinib)
START1
- Recommended starting dose of JAKAFI XR: 11 mg orally once daily
- Evaluate blood parameters before and during treatment with JAKAFI XR
- Consider increasing dose to 22 mg once daily after ≥3 days of treatment if ANC and platelet counts have not decreased by 50% or more relative to the first day of dosing
- JAKAFI XR is dosed orally and can be administered with or without food
- Patients must swallow JAKAFI XR tablets whole. Do not split, chew, or crush tablets
MONITOR1
- Dose modifications should be considered based on monitoring complete blood count (CBC), including platelet counts, absolute neutrophil count (ANC), and bilirubin; treatment interruption and restarting dosing; or other adverse reactions, as described in the Full Prescribing Information for JAKAFI XR
- If a dose is missed, patients should not take an additional dose, but should take the next usual prescribed dose
OPTIMIZE1
- Doses may be modified based on safety and efficacy
- Dose reductions may be used to manage side effects: JAKAFI XR 22 mg once daily may be reduced to JAKAFI XR 11 mg once daily
- Tapering may be considered after 6 months of treatment in patients with response who have discontinued therapeutic doses of steroids
- Taper JAKAFI XR by 1 dose level approximately every 8 weeks (22 mg once daily to 11 mg once daily)
- If aGVHD signs or symptoms recur during or after the taper of JAKAFI XR, consider retreatment
AVAILABLE DOSAGES
JAKAFI® (ruxolitinib) dosages
- 5 mg twice daily
- 10 mg twice daily
- 15 mg twice daily
- 20 mg twice daily
- 25 mg twice daily
JAKAFI XR dosages
- 11 mg once daily
- 22 mg once daily
- 33 mg once daily
- 44 mg once daily
- 55 mg once daily
aGVHD=acute graft-versus-host disease.
JAKAFI XR dose modifications
View the dosing modifications for patients with cytopenias, elevated total bilirubin (with or without liver GVHD), hepatic or renal impairment, and when JAKAFI XR is used with strong CYP3A4 inhibitors/inducers or fluconazole.
Dose modifications for cytopenias1
Clinically significant thrombocytopenia
- After supportive measures, reduce JAKAFI XR by 1 dose level
- When platelets recover to previous values, dosing may return to prior dose level
JAKAFI XR-related ANC <1 x 109/L
- Hold JAKAFI XR for up to 14 days; resume at 1 dose level lower upon recovery
See Full Prescribing Information for further details on dose modifications and use in special populations.
ANC=absolute neutrophil count.
Dose modifications for elevated total bilirubin1
Elevated total bilirubin without liver GVHD
- 3 to 5 × ULN: Continue JAKAFI XR at 1 dose level lower until recovery
- >5 to 10 × ULN: Hold JAKAFI XR for up to 14 days until bilirubin ≤1.5 × ULN; resume at current dose upon recovery
- >10 × ULN: Hold JAKAFI XR for up to 14 days until bilirubin ≤1.5 × ULN; resume at 1 dose level lower upon recovery
Elevated total bilirubin with liver GVHD
- >3 × ULN: Continue JAKAFI XR at 1 dose level lower until recovery
See Full Prescribing Information for further details on dose modifications and use in special populations.
GVHD=graft-versus-host disease; ULN=upper limit of normal.
Dose modifications for hepatic or renal impairment1
Hepatic impairment
- Mild, moderate, or severe (NCI criteria without liver GVHD): No starting dose adjustment needed
- Stage 1, 2, or 3 liver aGVHD: No starting dose adjustment needed
- Stage 4 liver aGVHD: Do not use JAKAFI XR
Renal impairment
- Moderate or severe: Do not use JAKAFI XR
- ESRD on dialysis: Do not use JAKAFI XR
- Avoid use of JAKAFI XR in patients with ESRD (CLcr <15 mL/min) not requiring dialysis
See Full Prescribing Information for further details on dose modifications and use in special populations.
aGVHD=acute graft-versus-host disease; CLcr=creatinine clearance; ESRD=end-stage renal disease; NCI=National Cancer Institute.
Dose modifications for concomitant use with strong CYP3A4 inhibitors or fluconazole1
Starting dose for patients with aGVHD
- Fluconazole doses ≤200 mg: Do not use JAKAFI XR
- Other CYP3A4 inhibitors: Monitor blood counts more frequently for toxicity and modify the JAKAFI XR dosage for adverse reactions if they occur
See Full Prescribing Information for further details on dose modifications and use in special populations.
aGVHD=acute graft-versus-host disease.
Reference: 1. JAKAFI/JAKAFI XR Prescribing Information. Wilmington, DE: Incyte Corporation.
